Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.47 |
| ▸ | HTR2C | P28335 | 9/20 | 0.40 |
| ▸ | HTR2A | P28223 | 7/20 | 0.40 |
| ▸ | HTR1A | P08908 | 6/20 | 0.40 |
| ▸ | HTR1D | P28221 | 5/20 | 0.40 |
| ▸ | HTR2B | P41595 | 7/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8405200 | 0.89 | MTNR1B (0.52) | MTNR1AMTNR1BGABRA1GABRB2 | |
| SCHEMBL20669648 | 0.82 | MTNR1A (0.41) | MTNR1AMTNR1BHTR2CHTR2AHTR1A | |
| SCHEMBL8463358 | 0.82 | MTNR1A (0.41) | MTNR1AMTNR1BHTR2CHTR2AHTR1A | |
| SCHEMBL20554279 | 0.82 | HTR2C (0.44) | MTNR1AMTNR1BHTR2CHTR2AHTR1A | |
| SCHEMBL30289569 | 0.82 | HTR2C (0.44) | MTNR1AMTNR1BHTR2CHTR2AHTR1A | |
| SCHEMBL6682400 | 0.82 | MTNR1A (0.44) | MTNR1AMTNR1BHTR2CHTR2AHTR1A | |
| SCHEMBL28218012 | 0.82 | MTNR1A (0.41) | MTNR1AMTNR1BHTR2CHTR2AHTR1A | |
| SCHEMBL22874980 | 0.81 | HTR2C (0.45) | MTNR1AMTNR1BHTR2CHTR2AHTR1A | |
| SCHEMBL29054671 | 0.81 | MTNR1A (0.41) | MTNR1AMTNR1BHTR2CHTR2AHTR1A | |
| SCHEMBL10157861 | 0.81 | HTR2C (0.44) | MTNR1AMTNR1BHTR2CHTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901147-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | MTNR1A 297/4885MTNR1B 350/4885HTR2C 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.